Meloxicam Bluefish: Uses, Dosage & Side Effects
Non-steroidal anti-inflammatory drug (NSAID) containing meloxicam for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis
Quick Facts: Meloxicam Bluefish
Key Takeaways
- Preferential COX-2 inhibitor: Meloxicam offers anti-inflammatory and analgesic effects with a somewhat lower gastrointestinal risk compared to traditional NSAIDs, though GI side effects remain the most common adverse reaction
- Once-daily dosing: The long half-life of approximately 20 hours allows convenient once-daily administration, taken with a meal
- Cardiovascular warning: Like all NSAIDs, meloxicam may increase the risk of heart attack and stroke, especially at higher doses and with prolonged use
- Not for acute pain: Meloxicam is not suitable for rapid relief of acute pain; its effects develop gradually over several days
- Maximum 15 mg per day: Never exceed the recommended maximum dose; elderly patients and those at increased risk should typically use 7.5 mg daily
What Is Meloxicam Bluefish and What Is It Used For?
Meloxicam Bluefish is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. It belongs to the oxicam class of NSAIDs and is a preferential inhibitor of cyclo-oxygenase-2 (COX-2). It is prescribed for adults and adolescents aged 16 years and older to manage symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Meloxicam works by inhibiting the production of prostaglandins, which are chemical mediators responsible for inflammation, pain and fever in the body. Unlike some older NSAIDs that inhibit both COX-1 and COX-2 enzymes equally, meloxicam preferentially targets COX-2, the enzyme primarily responsible for producing prostaglandins at sites of inflammation. This preferential inhibition means that meloxicam may offer a somewhat more favourable gastrointestinal safety profile compared to non-selective NSAIDs, although gastrointestinal side effects can still occur.
Meloxicam Bluefish is manufactured by Bluefish Pharmaceuticals AB, headquartered in Stockholm, Sweden. It is approved throughout the European Economic Area (EEA), including Denmark, Norway and Sweden. The medicine is a generic formulation, meaning it contains the same active ingredient in the same dose as the original branded meloxicam products, and has been demonstrated to be bioequivalent through rigorous regulatory testing.
Approved Indications
Meloxicam Bluefish is indicated for the following conditions:
- Osteoarthritis (OA): Short-term symptomatic treatment during acute exacerbations of osteoarthritis, a degenerative joint disease characterised by cartilage breakdown, pain and stiffness. Osteoarthritis is the most common form of arthritis worldwide, affecting over 500 million people according to the World Health Organization.
- Rheumatoid arthritis (RA): Long-term symptomatic treatment of rheumatoid arthritis, a chronic autoimmune inflammatory joint disease that can lead to joint destruction if untreated. NSAIDs like meloxicam are used alongside disease-modifying antirheumatic drugs (DMARDs) to manage pain and inflammation.
- Ankylosing spondylitis (AS): Long-term symptomatic treatment of ankylosing spondylitis, a chronic inflammatory condition primarily affecting the spine and sacroiliac joints. NSAIDs are considered first-line pharmacological therapy for AS according to the European Alliance of Associations for Rheumatology (EULAR) guidelines.
Meloxicam treats the symptoms of inflammatory joint diseases – it does not cure the underlying condition or prevent disease progression. For rheumatoid arthritis, it is typically used in combination with disease-modifying treatments. Always follow your prescriber’s guidance regarding the overall treatment plan for your condition.
What Should You Know Before Taking Meloxicam Bluefish?
Before taking Meloxicam Bluefish, you must inform your doctor about your complete medical history, particularly any history of gastrointestinal problems, cardiovascular disease, kidney or liver impairment, and any allergies to NSAIDs or aspirin. Meloxicam is contraindicated in several important clinical situations and has multiple significant drug interactions.
Contraindications
You must not take Meloxicam Bluefish if any of the following apply to you:
- Allergy (hypersensitivity) to meloxicam or any of the inactive ingredients in the tablet
- Known allergy or hypersensitivity to aspirin or other NSAIDs, including a history of asthma, nasal polyps, bronchospasm, or urticaria triggered by these medicines
- History of angioedema (sudden swelling of the face, lips, mouth or throat causing breathing difficulty) following use of aspirin or other NSAIDs
- Active peptic ulcer, recurrent peptic ulceration, or history of at least two episodes of gastrointestinal ulceration or bleeding
- Previous gastrointestinal bleeding or perforation related to NSAID therapy
- Severe hepatic impairment (liver failure)
- Severe renal impairment not receiving dialysis
- Active gastrointestinal bleeding, cerebrovascular bleeding, or other active bleeding disorders
- Severe heart failure
- During the last three months of pregnancy (see Pregnancy and Breastfeeding section)
- Age under 16 years
Warnings and Precautions
Talk to your doctor or pharmacist before taking Meloxicam Bluefish. Several important warnings apply to this medication:
NSAIDs including meloxicam may be associated with a small increased risk of myocardial infarction (heart attack) or cerebrovascular accident (stroke). This risk may increase with higher doses and longer duration of treatment. Do not exceed the recommended dose or use meloxicam for longer than prescribed. If you have heart disease, a history of stroke, or cardiovascular risk factors (hypertension, diabetes, hypercholesterolaemia, smoking), discuss the risks and benefits with your doctor before starting treatment.
Stop taking Meloxicam Bluefish immediately and contact your doctor if you notice gastrointestinal bleeding (which may present as black, tarry stools or bloody vomit) or develop ulceration symptoms (such as severe stomach pain). The risk of GI complications is higher in elderly patients and those with a history of peptic ulcer disease.
Life-threatening skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with meloxicam. These typically begin with reddish target-like spots or circular patches on the trunk, often with central blistering, and may be accompanied by mouth sores and flu-like symptoms. If you develop a rash or skin symptoms, stop taking Meloxicam Bluefish immediately and seek urgent medical attention. If you have ever had SJS or TEN, you must never use meloxicam again.
Exercise particular caution and inform your doctor if you have:
- A history of oesophagitis, gastritis, or any gastrointestinal disease (such as ulcerative colitis or Crohn’s disease)
- Asthma or a history of asthma
- Mild to moderate kidney or liver impairment
- Diabetes mellitus
- Heart disease, high blood pressure, or reduced blood volume (hypovolaemia)
- Elevated potassium levels (hyperkalaemia)
- Advanced age – elderly patients are at increased risk of adverse effects
- A history of fixed drug eruption with meloxicam or other oxicam-class NSAIDs (piroxicam)
Meloxicam is not suitable for the relief of acute pain because its onset of action is gradual. The medicine may also mask symptoms of infection, including fever. If you suspect you have an infection while taking meloxicam, contact your doctor promptly.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy: Meloxicam Bluefish must not be taken during the last three months of pregnancy (third trimester). During this period, it may cause serious harm to the unborn baby, including kidney and heart problems, an increased tendency to bleed, and delayed or prolonged labour. During the first six months of pregnancy, meloxicam should only be used if absolutely necessary and on medical advice, using the lowest dose for the shortest time possible. From gestational week 20 onwards, use for more than a few days may cause oligohydramnios (low amniotic fluid) or premature closure of the ductus arteriosus in the foetal heart.
Breastfeeding: NSAIDs are known to pass into breast milk, and meloxicam has been detected in the milk of lactating animals. Therefore, Meloxicam Bluefish is not recommended for women who are breastfeeding.
Fertility: Meloxicam, like other drugs that inhibit cyclo-oxygenase and prostaglandin synthesis, may impair female fertility. Women planning pregnancy or experiencing difficulty conceiving should inform their doctor, as discontinuation of meloxicam may be advisable.
Driving and Operating Machinery
Meloxicam may cause visual disturbances (including blurred vision), dizziness, drowsiness or fatigue. If you experience any of these effects, you should not drive or operate machinery. Other central nervous system disturbances may also occur. You are personally responsible for assessing your fitness to drive or perform tasks requiring alertness.
Important Information About Ingredients
Meloxicam Bluefish tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The tablets also contain sodium, but in amounts less than 1 mmol (23 mg) per tablet, meaning they are essentially sodium-free.
How Does Meloxicam Bluefish Interact with Other Drugs?
Meloxicam Bluefish can interact with numerous other medications. The most clinically significant interactions involve other NSAIDs, anticoagulants, lithium, methotrexate, ciclosporin, diuretics, antihypertensive agents, and SSRIs. Always inform your doctor or pharmacist about all medicines you are taking, including over-the-counter products.
Drug interactions with meloxicam can lead to increased toxicity, reduced therapeutic effects or increased risk of serious adverse reactions. The following table summarises the most important interactions:
Major Interactions
| Interacting Drug | Risk | Clinical Advice |
|---|---|---|
| Other NSAIDs & Aspirin | Significantly increased risk of gastrointestinal ulceration and bleeding | Avoid concomitant use; do not combine meloxicam with other NSAIDs or salicylates |
| Anticoagulants (warfarin, heparin, thrombolytics) | Increased risk of bleeding due to additive effects on haemostasis | Monitor closely; regular INR checks if co-prescribed with warfarin |
| Lithium | NSAIDs increase plasma lithium levels, potentially causing toxicity | Monitor lithium levels closely when starting, adjusting or stopping meloxicam |
| Methotrexate | NSAIDs reduce renal clearance of methotrexate, increasing haematological toxicity risk | Close monitoring of blood counts; consider dose adjustment |
| Ciclosporin | Increased risk of nephrotoxicity (kidney damage) | Monitor renal function; use the lowest effective dose of both drugs |
| Tacrolimus | Increased risk of nephrotoxicity | Monitor renal function during co-administration |
| Pemetrexed | Reduced renal clearance of pemetrexed, increasing toxicity | Avoid NSAIDs for at least 2 days before and after pemetrexed administration |
Other Important Interactions
| Interacting Drug | Effect | Action |
|---|---|---|
| ACE inhibitors, ARBs, Beta-blockers | Reduced antihypertensive effect; possible increased risk of renal impairment | Monitor blood pressure and renal function |
| Diuretics | Reduced diuretic effect; risk of acute renal failure with dehydration | Ensure adequate hydration; monitor renal function |
| SSRIs (antidepressants) | Increased risk of gastrointestinal bleeding | Consider gastroprotection; monitor for bleeding signs |
| Corticosteroids | Increased risk of gastrointestinal ulceration and bleeding | Consider gastroprotective therapy |
| Potassium salts | Increased risk of hyperkalaemia | Monitor potassium levels |
| Oral antidiabetics (sulfonylureas, nateglinide) | Possible increased risk of hypoglycaemia | Monitor blood glucose levels closely |
| Deferasirox | Increased risk of gastrointestinal adverse effects | Avoid concomitant use if possible |
| Cholestyramine | Accelerates elimination of meloxicam, reducing its effectiveness | Separate administration times; monitor efficacy |
| Intrauterine devices (IUDs) | NSAIDs may theoretically reduce the efficacy of IUDs | Consider additional contraception if concerned |
Meloxicam Bluefish should be swallowed with liquid together with a meal. Taking the tablet with food helps reduce gastrointestinal irritation and ensures consistent absorption. There is no specific restriction on the type of food, but excessive alcohol consumption should be avoided as it increases the risk of gastrointestinal bleeding.
What Is the Correct Dosage of Meloxicam Bluefish?
The usual dose of Meloxicam Bluefish is 7.5 mg to 15 mg once daily, depending on the condition being treated and individual patient factors. The total daily dose should be taken as a single dose, swallowed with water or another liquid, together with a meal. The maximum dose is 15 mg per day.
Always take this medicine exactly as your doctor or pharmacist has told you. Do not exceed the recommended dosage. The following dosage recommendations apply:
| Patient Group | Condition | Recommended Dose | Maximum Dose |
|---|---|---|---|
| Adults | Osteoarthritis (acute flare) | 7.5 mg once daily | 15 mg/day if needed |
| Adults | Rheumatoid arthritis | 15 mg once daily | 15 mg/day |
| Adults | Ankylosing spondylitis | 15 mg once daily | 15 mg/day |
| Elderly patients | RA or AS (long-term) | 7.5 mg once daily | 7.5 mg/day recommended |
| Patients at increased risk | Any indication | 7.5 mg once daily | 7.5 mg/day |
| Dialysis patients (severe renal impairment) | Any indication | Up to 7.5 mg once daily | 7.5 mg/day |
Adults
For osteoarthritis, the standard starting dose is 7.5 mg taken once daily. If symptoms are not adequately controlled, your doctor may increase the dose to 15 mg once daily. For rheumatoid arthritis and ankylosing spondylitis, the usual dose is 15 mg once daily. Your doctor may reduce this to 7.5 mg per day if you have risk factors for adverse effects or once symptoms are well controlled.
The entire daily dose should be taken at once, not split across the day. Take the tablet with water or another liquid, together with a meal. Do not exceed 15 mg of meloxicam in any 24-hour period.
Children and Adolescents
Meloxicam Bluefish 7.5 mg and 15 mg tablets are not recommended for use in children under 16 years of age. The safety and efficacy of meloxicam in this age group have not been established for the tablet formulation.
Elderly Patients
The recommended dose for long-term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg once daily. Elderly patients are at increased risk of serious gastrointestinal complications, renal impairment and cardiovascular events, so the lowest effective dose should be used for the shortest possible duration. Regular monitoring by a healthcare professional is advisable.
Kidney and Liver Impairment
No dose reduction is necessary for patients with mild to moderate kidney impairment (creatinine clearance above 25 mL/min) or mild to moderate liver impairment. For dialysis patients with severe kidney impairment, the dose should not exceed 7.5 mg per day. Meloxicam Bluefish is not recommended for patients with severe kidney impairment who are not on dialysis, and it is contraindicated in severe liver impairment.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a forgotten dose.
Overdose
If you have taken too much Meloxicam Bluefish, or if a child has accidentally swallowed the medicine, contact your doctor, hospital or poison control centre immediately for risk assessment and advice.
Symptoms of an acute NSAID overdose are generally limited to lethargy, drowsiness, nausea, vomiting and abdominal pain. These symptoms are usually reversible upon discontinuation. Gastrointestinal bleeding may occur. Severe poisoning can cause serious complications including hypertension, acute renal failure, impaired liver function, respiratory depression or arrest, coma, seizures, cardiovascular collapse and cardiac arrest. Immediate hypersensitivity reactions, including anaphylaxis, have been reported with therapeutic doses of NSAIDs and may also occur following an overdose.
What Are the Side Effects of Meloxicam Bluefish?
Like all medicines, Meloxicam Bluefish can cause side effects, although not everybody gets them. The most common side effects are gastrointestinal symptoms including indigestion, nausea, vomiting and abdominal pain. Serious but less common side effects include gastrointestinal bleeding, cardiovascular events, severe skin reactions and liver inflammation.
Stop taking Meloxicam Bluefish and seek immediate medical attention if you experience severe allergic reactions (difficulty breathing, facial swelling, skin blistering), gastrointestinal bleeding (black tarry stools, bloody vomit), or signs of a serious skin reaction (widespread rash with blistering).
The following side effects have been reported, organised by frequency:
Very Common
- Indigestion (dyspepsia)
- Nausea
- Vomiting
- Abdominal pain
- Constipation
- Flatulence (wind)
- Diarrhoea
Common
- Headache
Uncommon
- Anaemia (reduced haemoglobin)
- Dizziness or vertigo
- Drowsiness (somnolence)
- Allergic (hypersensitivity) reactions
- Elevated blood pressure
- Flushing (temporary facial redness)
- Sodium and fluid retention, oedema
- Hyperkalaemia (raised potassium)
- Belching (eructation)
- Gastritis (stomach inflammation)
- Stomatitis (mouth inflammation)
- Gastrointestinal bleeding
- Pruritus (itching), skin rash
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Angioedema (swelling of face, lips, throat)
- Elevated liver enzymes (transaminases, bilirubin)
- Elevated kidney function markers (creatinine, urea)
Rare
- Mood changes, nightmares, insomnia
- Abnormal white blood cell count (leukopenia)
- Thrombocytopenia (low platelets – increased bruising, nosebleeds)
- Tinnitus (ringing in the ears)
- Palpitations
- Oesophagitis (inflammation of the food pipe)
- Urticaria (hives)
- Visual disturbances including blurred vision, conjunctivitis
- Colitis (inflammation of the colon)
- Gastrointestinal ulceration or perforation
- Asthma attacks (in aspirin-sensitive individuals)
Very Rare
- Hepatitis (liver inflammation – may cause jaundice, abdominal pain, loss of appetite)
- Acute renal failure (especially in patients with risk factors)
- Gallbladder perforation
Frequency Not Known
- Confusion and disorientation
- Anaphylactic/anaphylactoid reactions (severe allergic reactions with breathing difficulty)
- Photosensitivity (skin rash caused by sunlight)
- Heart failure (reported with NSAID use)
- Agranulocytosis (complete loss of certain white blood cells – may cause sudden fever, sore throat, infections)
- Pancreatitis (inflammation of the pancreas)
- Female infertility, delayed ovulation
- Fixed drug eruption (recurring skin reaction at the same site)
- Small increased risk of heart attack or stroke
- Interstitial nephritis (kidney inflammation), renal papillary necrosis, proteinuria
Contact your doctor or go to the nearest emergency department immediately if you experience: black tarry stools or bloody vomit (signs of GI bleeding); sudden severe stomach pain; difficulty breathing or facial swelling (allergic reaction); widespread skin rash with blistering; yellowing of skin or eyes (jaundice); sudden high fever with severe sore throat (possible agranulocytosis).
If you experience visual disturbances while taking meloxicam, avoid driving or operating machinery. If you have a history of gastrointestinal problems and are using meloxicam long-term, particularly if you are elderly, contact your doctor if any GI symptoms develop so that appropriate monitoring can be arranged.
How Should You Store Meloxicam Bluefish?
Meloxicam Bluefish tablets should be stored out of the sight and reach of children. No special storage conditions are required – store at room temperature away from excessive heat and moisture. Do not use after the expiry date printed on the packaging.
Keep this medicine in the original blister packaging to protect it from moisture and light. There are no special temperature requirements; normal room temperature is suitable. Check the expiry date on the packaging before use – the expiry date refers to the last day of the stated month.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment and prevent accidental ingestion.
What Does Meloxicam Bluefish Contain?
Each Meloxicam Bluefish tablet contains 7.5 mg or 15 mg of the active substance meloxicam. The tablets also contain several inactive ingredients (excipients) including lactose monohydrate, microcrystalline cellulose, and magnesium stearate.
Active Ingredient
The active substance is meloxicam, present at a strength of 7.5 mg or 15 mg per tablet. Meloxicam is a member of the oxicam class of NSAIDs and acts as a preferential COX-2 inhibitor.
Inactive Ingredients (Excipients)
- Microcrystalline cellulose
- Pregelatinised starch
- Maize starch
- Sodium citrate
- Colloidal anhydrous silica
- Magnesium stearate
- Lactose monohydrate
Appearance and Packaging
The 7.5 mg tablet is a yellowish, round tablet with a bevelled edge and a score line on one side. Note that the score line on the 7.5 mg tablet is only intended to help with swallowing, not for dividing into equal doses. The 15 mg tablet is also yellowish and round with a bevelled edge and a score line, and can be divided into two equal doses.
The tablets are supplied in PVC/PVDC/aluminium blister packs in pack sizes of 10, 20, 30 and 100 tablets. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Meloxicam Bluefish
Both meloxicam and ibuprofen are NSAIDs, but they differ in several important ways. Meloxicam is a preferential COX-2 inhibitor with a long half-life of approximately 20 hours, allowing once-daily dosing and potentially offering a somewhat lower risk of gastrointestinal side effects. Ibuprofen is a non-selective NSAID with a shorter half-life (2–4 hours), typically requiring dosing three to four times daily. Meloxicam is prescription-only, while ibuprofen is available over the counter in many countries. Your doctor will determine which NSAID is most appropriate for your specific condition and risk profile.
While there is no absolute prohibition, it is strongly advisable to limit or avoid alcohol consumption while taking meloxicam. Both alcohol and NSAIDs can irritate the stomach lining and increase the risk of gastrointestinal bleeding and ulceration. Combining the two significantly increases this risk. If you do choose to drink alcohol, keep consumption to a minimum and watch for signs of stomach irritation such as pain, nausea or dark stools.
Meloxicam reaches peak blood concentration approximately 5 to 6 hours after oral administration. Some pain relief may be noticed within the first day or two of treatment, but the full anti-inflammatory effect typically develops over several days of regular use. This is one reason why meloxicam is not suitable for immediate relief of acute pain. If you feel no improvement after several days of treatment, speak to your doctor – they may need to adjust your dose or consider an alternative treatment.
Yes. Meloxicam Bluefish is a generic medicine that contains the same active ingredient (meloxicam) in the same strength as other branded and generic meloxicam products. Before approval, generic medicines must demonstrate bioequivalence to the reference product through rigorous clinical testing, meaning they deliver the same amount of active drug to the body at the same rate. The only differences may be in the inactive ingredients (excipients), appearance and packaging. Meloxicam Bluefish is approved throughout the European Economic Area.
In many cases, paracetamol (acetaminophen) can be used alongside meloxicam for additional pain relief, as they work through different mechanisms. Paracetamol is not an NSAID and does not carry the same gastrointestinal or cardiovascular risks. However, you should always consult your doctor or pharmacist before combining any medications. Do not take meloxicam together with other NSAIDs (such as ibuprofen, diclofenac or naproxen), as this significantly increases the risk of side effects without providing additional benefit.
All information is based on the approved Summary of Product Characteristics (SmPC) for Meloxicam Bluefish, regulatory publications from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the British National Formulary (BNF), and international clinical guidelines from the World Health Organization (WHO) and the European Alliance of Associations for Rheumatology (EULAR). Evidence levels follow the GRADE framework, with clinical recommendations supported by systematic reviews and randomised controlled trials.
References
- European Medicines Agency (EMA). Meloxicam – Summary of Product Characteristics. Available at: www.ema.europa.eu.
- U.S. Food and Drug Administration (FDA). Meloxicam – FDA Prescribing Information. Available at: www.fda.gov.
- British National Formulary (BNF). Meloxicam – Drug Monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd edition (2023). Geneva: WHO.
- Derry S, et al. Oral non-steroidal anti-inflammatory drugs (NSAIDs) for osteoarthritis. Cochrane Database of Systematic Reviews. 2023. doi:10.1002/14651858.CD004257.
- Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet. 2013;382(9894):769–779.
- European Alliance of Associations for Rheumatology (EULAR). 2023 Updated EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2023.
- Ramiro S, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the Rheumatic Diseases. 2023;82(1):19–34.
- FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine. 2001;345(6):433–442.
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians, clinical pharmacologists and pharmacists with expertise in pharmacology and rheumatology. All content follows the GRADE evidence framework and is based on peer-reviewed research, regulatory documents and international clinical guidelines.
Medical Writers
Licensed physicians and pharmacologists with clinical experience in rheumatology and pain medicine
Medical Reviewers
Independent medical review board verifying clinical accuracy, completeness and adherence to international guidelines
All iMedic content is independently produced with no commercial funding or pharmaceutical sponsorship. We follow a strict editorial process with peer review, fact-checking and regular updates based on the latest evidence. Read our editorial standards.